Advertisement
Canada markets close in 1 hour 11 minutes

  • S&P/TSX

    21,637.60
    -18.45 (-0.09%)
     

  • S&P 500

    5,010.51
    -11.70 (-0.23%)
     

  • DOW

    37,762.37
    +9.06 (+0.02%)
     

  • CAD/USD

    0.7263
    -0.0001 (-0.02%)
     

  • CRUDE OIL

    82.74
    +0.05 (+0.06%)
     

  • Bitcoin CAD

    86,934.62
    +1,946.03 (+2.29%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • GOLD FUTURES

    2,395.30
    +6.90 (+0.29%)
     

  • RUSSELL 2000

    1,942.59
    -5.36 (-0.28%)
     

  • 10-Yr Bond

    4.6430
    +0.0580 (+1.26%)
     

  • NASDAQ

    15,609.25
    -74.12 (-0.47%)
     

  • VOLATILITY

    18.15
    -0.06 (-0.33%)
     

  • FTSE

    7,877.05
    +29.06 (+0.37%)
     

  • NIKKEI 225

    38,079.70
    +117.90 (+0.31%)
     

  • CAD/EUR

    0.6817
    +0.0015 (+0.22%)
     
MARKETS LIVE BLOG:

STOCKS RISE AS TECHS REVIVE, WITH NETFLIX EARNINGS ON TAP

Tesla shares slide to 52-week low; stock is down roughly 40% year-to-date

Bellus: 4Q Earnings Snapshot

Associated Press
Updated ·1 min read

LAVAL, Quebec (AP) _ Bellus Health Inc. (BLU) on Thursday reported a loss of $7.5 million in its fourth quarter.

The Laval, Quebec-based company said it had a loss of 10 cents per share.

The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 13 cents per share.

The drug developer posted revenue of $4,000 in the period.

For the year, the company reported that its loss widened to $31.8 million, or 54 cents per share. Revenue was nearly unchanged at $15,000.

In the final minutes of trading on Thursday, the company's shares hit $3.92. A year ago, they were trading at $9.27.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BLU at https://www.zacks.com/ap/BLU